ArticleGut pathogens2022
Designing a novel multi-epitope vaccine to evoke a robust immune response against pathogenic multidrug-resistant Enterococcus faecium bacterium.
Article in Gut pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Immunoinformatics Design of a Broad-Spectrum Multi-Epitope Vaccine Targeting HA2 and M1 of H9N2 AIV.Microorganisms · 2026Article
- Multi-epitope mRNA vaccine and protein vaccine protect mice against Toxoplasma gondii.Parasites & vectors · 2026Article
- Review
- In-silico design of a multi-epitope vaccine candidate against Strongyloides stercoralis.BMC infectious diseases · 2026Article
- Designing a multi-epitope vaccine against yellow fever virus using immunoinformatics approaches.Open medicine (Warsaw, Poland) · 2026Article
- Article
- Taming Superbugs: Current Progress and Challenges in Combating ESKAPE Pathogens.Pathogens (Basel, Switzerland) · 2025Review
- Multi-epitope vaccine design against human metapneumovirus via reverse vaccinology and molecular modelling.Scientific reports · 2025Article
- Towards precision epitopes based vaccine againstBiochemistry and biophysics reports · 2025Article
- Engineering a multi-epitope chimera derived from Acinetobacter baumannii CAM87009.1 and FilF fimbriae proteins: immunogenic and antibiofilm activity.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Protection of Mice Vaccinated with a New B Cell and T Cell Epitopes Cocktail from Staphylococcus aureus Challenge in Skin Infection Model.Current microbiology · 2025Article
- FcRn-guided antigen trafficking enhances cancer vaccine efficacy.Cancer immunology, immunotherapy : CII · 2025Article
- Article
- Article
- Optimized multi-epitope neoantigen human cytomegalovirus vaccine based on adenovirus vectors elicits potent antiviral immunity.Frontiers in immunology · 2025Article
- Peptide vaccines: an innovative therapeutic approach against antibiotic-resistant bacterial infections.Frontiers in immunology · 2025Review
- Development of a multi-epitope vaccine from outer membrane proteins and identification of novel drug targets againstFrontiers in immunology · 2025Article
- Next-generation sequencing and immuno-informatics for designing a multi-epitope vaccine against HSV-1-induced uveitis.Frontiers in immunology · 2025Article
- Development of multi-epitope mRNA vaccine againstSynthetic and systems biotechnology · 2024Article
- Advances of computational methods enhance the development of multi-epitope vaccines.Briefings in bioinformatics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enterococcus faecium is an emerging ESKAPE bacterium that is capable of causing severe public health complications in humans. There are currently no licensed treatments or vaccinations to combat the deadly pathogen. We aimed to design a potent and novel prophylactic chimeric vaccine against E. faecium through an immunoinformatics approach The antigenic Penicillin-binding protein 5 (PBP 5) protein was selected to identify B and T cell epitopes, followed by conservancy analysis, population coverage, physiochemical assessment, secondary and tertiary structural analysis. Using various immunoinformatics methods and tools, two linear B-cell epitopes, five CTL epitopes, and two HTL epitopes were finally selected for vaccine development. The constructed vaccine was determined to be highly immunogenic, cytokine-producing, antigenic, non-toxic, non-allergenic, and stable, as well as potentially effective against E. faecium. In addition, disulfide engineering, codon adaptation, and in silico cloning, were used to improve stability and expression efficiency in the host E. coli. Molecular docking and molecular dynamics simulations indicated that the structure of the vaccine is stable and has a high affinity for the TLR4 receptor. The immune simulation results revealed that both B and T cells had an increased response to the vaccination component. Conclusively, the in-depth in silico analysis suggests, the proposed vaccine to elicit a robust immune response against E. faecium infection and hence a promising target for further experimental trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.